Preclinical Testing of Metabolic Inhibitors with Erlotinib in Renal Medullary Carcinoma

Authors

Daisha Lewis, The University of Texas MD Anderson Cancer CenterFollow
Dalia Karimi, The University of Texas MD Anderson Cancer Center
Pedro Pesquera, The University of Texas MD Anderson Cancer Center
Tapati Maity, The University of Texas MD Anderson Cancer Center
Manuel Ozambela, The University of Texas MD Anderson Cancer Center
Pavlos Msaouel, The University of Texas MD Anderson Cancer Center
Niki M. Zacharias, The University of Texas MD Anderson Cancer Center

Files

Program Affiliation

Partnership for Careers in Cancer Science and Medicine Summer Program

Keywords

RMC, Drug Assay, Erlotinib, Telaglenastat

Recommended Citation

Lewis, Daisha; Karimi, Dalia; Pesquera, Pedro; Maity, Tapati; Ozambela, Manuel; Msaouel, Pavlos; and Zacharias, Niki M., "Preclinical Testing of Metabolic Inhibitors with Erlotinib in Renal Medullary Carcinoma" (2023). 2023 Summer Experience. 94.
https://openworks.mdanderson.org/sumexp23/94